Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

BVL3572S inhibits HisC and AlaA, exploiting vitamin B6 dependency to kill Mycobacterium tuberculosis.

Zainab Edoo Astrid Lenne-Delmotte C. Grosse Marie Devaere Marion Michel G. Caron Ernesto Anoz-Carbonell Kamel Djaout Rosangela Frita C. Gaudin Line Hofmann Sophie Lecher Véronique Megalizzi A. Michelotti D. Rengel Pauline Rouan S. Slupek L. Tawk R. Antoine Hanna Kulyk Glenn E. Dale C. Guilhot N. Willand G. Lippens R. Wintjens Alain R. Baulard
Aug 2026 · Cell Chemical Biology · 0 citations
Medicine

TL;DR

These findings establish BVL3572S as a promising lead compound acting through a previously unexploited, multitarget mechanism, and display strong synergy with the antitubercular drug D-cycloserine.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Sep 2026

The Dephospho-CoA Kinase of Mycobacterium tuberculosis: Molecular Mechanism and Function

The found that the S15A, R145A or N175A mutants showed markedly reduced activity, whereas the K14A mutation completely abolished activity, and deletion of residues 27-101 (Δ27-101) led to a significant loss of function.

Da-Feng Liu, Hua-Shui Deng, Hong-Jun Song · 0 citations
Aug 2026

Molecular insights into inhibitor action on the catalytic activity of Mycobacterium tuberculosis cystathionine β-synthase enzyme.

These findings provide a mechanistic rationale for MtbCBS inhibition, and the unexplored roles of these key residues can be considered in the design of next-generation inhibitors targeting CBS enzymes implicated in infectious diseases, cancer, and neurological disorders.

Sainath Polepalli, Anupam Roy, Bapan Mondal et al. · 0 citations
Open access Sep 2026

Discovery of new diaminoquinazolines against Mycobacterium tuberculosis: chemical synthesis and in vitro evaluation

Despite the availability of multiple treatment options, the emergence of drug-resistant Mycobacterium tuberculosis (Mtb) strains presents a significant health concern worldwide. This necessitates the development of novel antitubercular agents with distinct mechanisms of action. Diaminoquinazolines (DAQs) have demonstra...

Mukul Kore, N. Sundaramoorthy, Saqib Kidwai et al. · 0 citations
Open access Sep 2026

The Flexible Peripheral Segments Modulate the Catalytic Activity of the FAD-Containing Monooxygenase EthA from Mycobacterium tuberculosis

An AlphaFold2-predicted structural model of Mtb EthA is reported and it is suggested that flexible peripheral regions may constrain catalytic activity, offering insights into ETH activation and potential mechanisms of drug resistance.

Da-Feng Liu, Xie-Ping Sun, Feng Yu et al. · 0 citations
Sep 2026

Design, Synthesis, and Antimicrobial Activity of Novel Cyt- bd Inhibitors Targeting Energy Compensation in Mycobacterium tuberculosis

This study supports co-targeting Cyt-bd and Cyt-bcc as a therapeutic strategy for drug-resistant tuberculosis by finding a structure–activity relationship study starting from the previously identified Cyt-bd inhibitor 12, leading to the discovery of 17aa (YH-685).

Qiao Qin, Zhuo-Heng Liu, Chen-Yi Cheung et al. · 0 citations
Aug 2026

Synthesis, multi-target enzyme inhibition, and in silico evaluation of phthalimide derivatives with relevance to tuberculosis-associated pathophysiology.

A new series of phthalimide derivatives was synthesized and structurally characterized through 1H NMR and 13C NMR, with further optimization performed at the DFT level, identifying C15 and C17 as promising lead compounds for further optimization as multitarget enzyme inhibitors.

A. Khushal, Sara Khan, Umar Farooq et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.